We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

242 hedge funds and large institutions have $1.1B invested in Collegium Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 77 increasing their positions, 97 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

235% more call options, than puts

Call options by funds: $617K | Put options by funds: $184K

19% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 26

1% more funds holding

Funds holding: 240 → 242 (+2)

1.38% less ownership

Funds ownership: 115.58% → 114.2% (-1.4%)

12% less capital inflows, than outflows

Capital inflows: $97.5M | Capital outflows: $110M

21% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 97

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
242
Holders Change
+2
Holders Change %
+0.83%
% of All Funds
3.23%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
31
Increased
77
Reduced
97
Closed
26
Calls
$617​K
Puts
$184​K
Net Calls
+$433​K
Net Calls Change
+$3​K

COLL Hedge Fund Activity: Q1 2025 in Review

242 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2025, worth a combined $1.1B — up 2.9% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new COLL positions and 26 closed out — a net gain of 5 holders — while 77 added to existing stakes and 97 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $19.9M. The largest seller was Pacer Advisors, cutting an estimated $52.7M.

  • 242 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2025, up from 240 in Q4 2024.
  • Funds reported $1.1B of Collegium Pharmaceutical stock for Q1 2025, up 2.9% quarter-over-quarter.
  • 31 funds opened new Collegium Pharmaceutical positions in Q1 2025 and 26 closed out, a net change of +5 holders.
  • The largest Collegium Pharmaceutical buyer in Q1 2025 was Rubric Capital Management (New York), an estimated $19.9M added.
  • The largest Collegium Pharmaceutical seller in Q1 2025 was Pacer Advisors, an estimated $52.7M sold.

Based on aggregated 13F filings for Q1 2025.